sur Theranexus (EPA:ALTHX)
Half-Yearly Review of the Theranexus Liquidity Contract
Biopharmaceutical company Theranexus, which specializes in the treatment of rare neurological diseases, has published the half-yearly results of its liquidity agreement with Portzamparc. As of June 30, 2025, the liquidity account showed 41,770 Theranexus shares and €31,202.02. In comparison, the balance sheet as of December 31, 2024, showed 110,572 shares and €36,223.69.
A withdrawal of 50,000 euros took place on March 6, 2025. During the first half of 2025, 67,331 shares were purchased for 54,017.33 euros through 207 transactions, while 136,133 shares were sold for 98,995.66 euros through 271 transactions.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus